G1 Therapeutics : J.P. Morgan Healthcare Conference Presentation

Optimizing Chemotherapy,

Advancing Survival

39th Annual J.P. Morgan Healthcare Conference

January 13, 2021

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward- looking statements. Forward-looking statements in this presentation include, but are not limited to, those relating to the therapeutic potential of trilaciclib, rintodestrant and lerociclib, the timing of marketing applications in the U.S. for trilaciclib in SCLC, trilaciclib's possibility to improve patient outcomes across multiple indications, rintodestrant's potential to be best-in-class oral SERD, our reliance on partners to develop and commercial licensed products, and the impact of pandemics such as COVID-19 (coronavirus), and are based on the company's expectations and assumptions as of the date of this presentation. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the company's actual results to differ from those expressed or implied in the forward-looking statements in this presentation are discussed in the company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, the company's ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the company's initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development- stage company; and market conditions. Trilaciclib, rintodestrant and lerociclib are not approved by the FDA. The safety or effectiveness of trilaciclib, rintodestrant and lerociclib have not been established by the FDA. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

2

Transformed Company Heading into a Pivotal 2021

2020

Trilaciclib

2021

Trilaciclib is a cornerstone therapy:

• Near-termU.S. launch in SCLC (Priority Review)
• Pipeline-in-a-moleculedevelopment opportunity

Partner for

Greater China

Rintodestrant

Lerociclib

CDK2

Discovery Platform

OUT-LICENSED

OUT-LICENSED

Rintodestrant + palbociclib Phase 2 data expected 2Q

$207M cash on hand

(as of December 31, 2020)

Streamlined company focused on maximizing

the development and commercialization of trilaciclib

3

Chemo to Remain Mainstay Therapy Despite Shortcomings

Over 1 million cancer patients receive chemo in the U.S. each year

• Cost-efficientand effective treatment option expected to remain backbone of SoC
• Established high water-mark that has proven difficult to exceed head-to-head
• Immunotherapy with chemo has demonstrated the best results in many tumors

Two Critical Areas of Unmet Need

Proactively reducing the damaging		Meaningfully improving overall
consequences of chemotherapy		survival in broad populations

High unmet need for new therapies that can significantly reduce myelosuppression

and meaningfully improve efficacy across patient populations

4

Trilaciclib: Novel Approach to Address Shortcomings of Chemo

Trilaciclib

Transient IV CDK4/6 inhibitor

Temporarily blocks progression through the cell cycle

Leads to multiple potential downstream effects

Protects HSPCs and myeloid and lymphoid cell lineages from damage caused by chemotherapy1-3

Neutrophils

T-lymphocytes

Erythrocytes

B-lymphocytes

Platelets

Ability to improve the immune response when

administered with chemotherapy4-9

Enhances T-cell activation

Favorably alters tumor microenvironment

Potential to benefit patients receiving chemotherapy across multiple tumor types

1. Weiss J, et al. Ann Oncol. 2019 Oct; 30(10): 1613-1621. 2. He S, et al. Sci Transl Med. 2017;9:eaal3986. 3. Bisi JE, et al. Mol Cancer Ther. 2016;15:783-93. 4. Tan A, et al. Lancet Oncol. 2019 Sep 28. 5. Zhang J, et al. Nature. 2018;553:91-95. 6. Jerby-Arnon L, et al. Cell. 2018;175:984-997. 7. Goel S, et al. Nature. 2017;548:471-475. 8. Deng J, et al. Cancer Discov. 2018;:216-233. 9.

O'Shaugnessy et al., 2020 San Antonio Breast Cancer Symposium (SABCS), Poster #PD1-06.	5

Trilaciclib Demonstrated Meaningful Benefits Across Studies

Myelopreservation Impact1-5		Anti-Tumor Efficacy Impact6-11

Protects myeloid

cell lineages

Protects lymphoid

cell lineages

Improves immune

response

Potential to provide myelopreservation and/or anti-tumor efficacy benefits

in patients treated with chemotherapy

1. Weiss J, et al. Ann Oncol. 2019 Oct; 30(10): 1613-1621. 2. He S, et al. Sci Transl Med. 2017;9:eaal3986. 3. Bisi JE, et al. Mol Cancer Ther. 2016;15:783-93. 4. Weiss et al. MASCC Oral Presentation, Abstract #MASCC9-0845. 5. Tan A, et al. Lancet Oncol. 2019 Sep 28. 6. Ferrarotto et al., 2020 North America Conference on Lung Cancer (NACLC), Abstract # OA03.08. 7. Zhang J,

et al. Nature. 2018;553:91-95. 8. Jerby-Arnon L, et al. Cell. 2018;175:984-997. 9. Goel S, et al. Nature. 2017;548:471-475. 10. Deng J, et al. Cancer Discov. 2018;:216-233. 11. O'Shaugnessy et al.,	6
2020 San Antonio Breast Cancer Symposium (SABCS), Poster #PD1-06.

Significant Expansion Opportunities for Trilaciclib

Myelopreservation Focus

Anti-Tumor Efficacy Focus

Protecting the bone marrow from the

damaging consequences of

myelotoxic chemo:

• Common SCLC regimens*
• 5-FUbased regimens
• Other myelotoxic regimens

Myelopreservation

Preserving / activating the immune system:

• Alternative to I/O treatment
• Following I/O treatment
• In tumors less responsive to I/O

Improved Survival (single agent)

Improving efficacy of immunotherapy

and chemo combinations:

• With PD-1/PD-L1 inhibitors
• With other immunotherapies

Improved Survival (combinations)

+ Chemo Backbone

* Expected 1Q 2021 U.S. launch in ES-SCLC

Optimizing development plan across three core growth platforms

will enable trilaciclib to benefit as many patients as possible

7

Pipeline-in-a-Molecule Opportunity Beyond ES-SCLC Launch

Key Study Objective:

Myelopreservation

Improved Survival (single agent)

Improved Survival (combinations)

		REGISTRATIONAL TRIALS
POTENTIAL
		1L / 2L TNBC
APPROVAL /
U.S. LAUNCH
	1L CRC	Initiating in
1Q 2021
	1H 2021
		Initiated in
ES-SCLC
2020

			PHASE 2 STUDIES
						+ Milestones and
									Royalties
						Other Tumors
						TBD
					1L Bladder
					Cancer
			2L / 3L NSCLC		Initiating in
				1H 2021
								Trilaciclib
	Neoadjuvant		Initiating in
	Breast Cancer		1H 2021						Opportunity

Initiated in

2020

Aggressively pursuing development in areas of high strategic importance where trilaciclib is most likely to provide meaningful benefits to patients

8

2021 Key Objectives

1. Obtain U.S. approval for ES-SCLC and successfully launch trilaciclib in 1Q
2. Establish trilaciclib as Standard of Care for ES-SCLC patients in the U.S.
3. Maximize long-term value of trilaciclib by executing robust development plan
4. Evaluate partnership options for rintodestrant following combination data readout in 2Q
5. Continue managing investor capital efficiently

Focused on successfully launching trilaciclib in ES-SCLC and

accelerating development into other areas where chemotherapy is used

9

2021 Key Objectives

1. Obtain U.S. approval for ES-SCLC and successfully launch trilaciclib in 1Q
2. Establish trilaciclib as Standard of Care for ES-SCLC patients in the U.S.
3. Maximize long-term value of trilaciclib by executing robust development plan
4. Evaluate partnership options for rintodestrant following combination data readout in 2Q
5. Continue managing investor capital efficiently

10

Prepared for Trilaciclib Approval and U.S. Launch in 1Q21

NDA Discussions on Track

• PDUFA action date for SCLC indication: February 15th, 2021
• NDA under "Priority Review"
• Less complex CMC application given small molecule compound

Pre-Launch Activities Ongoing

• Identified HCP targets
• Profiled key accounts
• Engaged payors
• Educating leading patient advocacy organizations

Ready for 1Q Launch

• G1 infrastructure in place
• • Marketing
  • Market Access
  • Commercial Operations
  • Medical Affairs team
  • Manufacturing and supply chain
• Boehringer Ingelheim field sales team trained and ready1
• • Experienced lung cancer team
  • Incentivized structure (% net sales)

Following NDA approval, we are ready to make this important new treatment available

to the majority of patients with ES-SCLC undergoing chemotherapy in the U.S.

1. Three-year agreement where Boehringer Ingelheim leads sales force engagement initiatives for trilaciclib in the U.S. for the initial ES-SCLC indication. The agreement does not extend to additional indications.

11

Opportunity to Meaningfully Impact the Lives of Many Patients

~30k ES-SCLC Patients

Treated Annually in the U.S.1

1L Treated Patients1,2

17.5k

2L Treated Patients1,3

9.5k

3L Treated Patients1,4

2.5k

ES-SCLC patients predominately treated with highly myelosuppressive chemo regimens

• Limited successful innovation given aggressiveness of disease (1L median OS ~1 year5)
• Standard treatment includes 4 to 6 cycles of chemo

Payor research and discussions indicate potential broad patient access to trilaciclib

• Anticipate pricing product above supportive care treatments and below therapeutics
• ~60% of ES-SCLC patients covered by Medicare (expect Medicare to cover label at launch)

Trilaciclib provides a meaningful improvement for SCLC patients and

has potential to generate near-term revenue to further support ongoing development

1. Based on incidence of 25k for all SCLC with 81% of patients being diagnosed at Extensive Stage; Decision Resources Group, Small Cell Lung Cancer Disease Landscape & Forecast, March 2020.
2. Based on 22k 1L SCLC total patients (20K de novo ES-SCLC and 2K late relapse LS-SCLC) treated at an assumed 80% treatment rate (from 2020 internal primary market research).
3. Based on 12.5k 2L SCLC total patients (11k progressed 1L SCLC and 1.5k early relapse LS-SCLC) treated at an assumed 72% treatment rate (from 2020 internal primary market research).

4. Based on 5k 3L SCLC total patients treated at an assumed 50% treatment rate (from 2020 internal primary market research).	12
5. Demonstrated in trilaciclib G1T28-02 and G1T28-05 study control arms.

Three Core Goals for a Successful U.S. ES-SCLC Launch

Increase Awareness of Myelosuppression

Communicate the

Unique Benefits of

Trilaciclib

Optimize Early

Experience

Increase awareness of the significant multi-lineage impact of myelosuppression on clinical outcomes, costs, and patients' QoL

Educate prescribers, payers, and patients on the benefits of trilaciclib's proactive multi-lineage protection

Gain inclusion into relevant guidelines / pathways; enable broad patient access; and ensure ease of use for prescribers / nurses / staff

Focused on ensuring patients with ES-SCLC can benefit from trilaciclib

first time and every time they are treated with chemotherapy

13

Prescribers are Enthusiastic to Use Trilaciclib

Prescriber Enthusiasm to Use Trilaciclib for Patients with SCLC Following Education

1L ES-SCLC

22%

38%

17%

77%

2L ES-SCLC

23%

36%

18%

77%

	Extremely Enthusiastic		Very Enthusiastic		Moderately Enthusiastic

Source: internal market research conducted July 2020 (n=153 oncologists)

Education will be key to establish trilaciclib as a Standard of Care

for patients with ES-SCLC receiving chemotherapy

14

2021 Key Objectives

1. Obtain U.S. approval for ES-SCLC and successfully launch trilaciclib in 1Q
2. Establish trilaciclib as Standard of Care for ES-SCLC patients in the U.S.
3. Maximize long-term value of trilaciclib by executing robust development plan
4. Evaluate partnership options for rintodestrant following combination data readout in 2Q
5. Continue managing investor capital efficiently

15

The Burden of Chemotherapy

HEMATOLOGIC EVENT:

CONSEQUENCE:

RESPONSE:

M Y E L O S U P P R E S S I O N

An unavoidable consequence of chemo that impacts patient safety, healthcare system costs and QoL

NEUTROPENIA	ANEMIA	THROMBOCYTOPENIA
Risk of infection	Fatigue	Risk of bleeding
G-CSF use	RBC transfusions	Platelet transfusions
(associated bone pain)	and ESA rescue
Increased	Chemotherapy	Hospitalizations
dose reductions	and unscheduled
healthcare costs
and delays	patient care

Myelosuppression has a significant negative impact on

clinical outcomes, healthcare costs, and overall patient quality of life

16

Trilaciclib Meaningfully Reduces Myelosuppression in SCLC

Reduced Incidence of Multi-lineage Myelosuppression in 1L‒3L SCLC1

(pooled data across our 3 randomized placebo-controlleddouble-blind trials)

	P<0.0001
60%	53%					P=0.028	P=0.0067
40%						36%
				32%
20%				P=0.089	20%	20%
11%			9%
				3%
0%
Severe Neutropenia	Febrile Neutropenia		Grade 3/4 Anemia	Grade 3/4
			Chemotherapy + Placebo		Chemotherapy + Trilaciclib	Thrombocytopenia

Clinical Results: Trilaciclib consistently demonstrated meaningful reductions in

hematologic adverse events across multiple randomized SCLC studies

1. Weiss et al., 2020 American Society of Clinical Oncology (ASCO), Abstract #384.

17

Trilaciclib Expected to Drive Significant Payor/Hospital Savings

Average Total Annual Cost Per Patient with a Grade 3/4

Hematologic Event (Jan 2016 - Dec 2019)1

Neutropenia	$131,047
Anemia	$95,954
Thrombocytopenia	$90,053
Average total annual cost per
patient without a grade 3/4
hematologic event:		$67,802

Cost savings from less hematologic events largely driven by:

• Reduced interventions (e.g., G-CSF, ESA)
• Fewer required transfusions
• Fewer complications and hospitalizations

Payor Impact: Trilaciclib's ability to reduce the severe hematologic consequences of

chemotherapy expected to result in a budget-neutral to savings-positive impact

1. Epstein et al, Journal of Clinical Oncology May 25, 2020; 38, no. 15_suppl

18

Trilaciclib Improves Patients' Quality of Life

89% of cancer patients with myelosuppression rate it as having a moderate to major impact on their life1:

"…the overall fatigue was the worst.

It stole my energy and joy for both life and family. It made me want to quit chemo numerous times."

"I don't feel like doing ANYTHING some days.

It's like depression but completely physical."

"Did not get out as much, not able to work,

always feeling tired."

Trilaciclib helps patient functioning in ES-SCLC patients:

Median Time to Deterioration2

(pooled data from three randomized, placebo-controlled,double-blind trials)

Measure	Placebo		Improvement
(months)		(months)
Fatigue	2.3		4.7
Anemia -TOI	3.8		3.4
(Trial Outcome Index)
Functional Well Being	3.8		3.8

Patient Benefit: Trilaciclib's proactive protection enables better quality of life

for patients in this palliative treatment setting

1. Epstein et al, Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors; Advances in Therapy, July 2020

2. Weiss et al., MASCC Oral Presentation 2019, Abstract #MASCC 9-0845	19

Opportunity for Trilaciclib to Become Standard of Care in SCLC

Clinical Results: Meaningfully reduces the hematologic adverse events in SCLC

Payer Impact: Provides cost savings for system (trilaciclib expected to be budget neutral or better)

Patient Benefits: Improves the overall quality of life for patients

Heightened awareness of myelosuppression due to the COVID pandemic

may further encourage adoption of trilaciclib as a Standard of Care

20

2021 Key Objectives

1. Obtain U.S. approval for ES-SCLC and successfully launch trilaciclib in 1Q
2. Establish trilaciclib as Standard of Care for ES-SCLC patients in the U.S.
3. Maximize long-term value of trilaciclib by executing robust development plan
4. Evaluate partnership options for rintodestrant following combination data readout in 2Q
5. Continue managing investor capital efficiently

21

Aggressively Pursuing Development in Common Tumor Types

300,000

250,000

200,000

150,000

100,000

50,000

0

Patients Receiving Chemo2:

U.S. Incidence and Deaths1

Estimated New Cases

Estimated Deaths

Breast	Lung	Prostate	Colon and Rectal	Melanoma	Bladder	Non-Hodgkin	Kidney Cancer
			(Combined)			Lymphoma
110k	125k	30k	115k	<5k	20k	45k	<5k

Shading indicates areas of ongoing or soon to be initiated G1 sponsored studies

G1 has / will soon initiate sponsored studies

in many of the most common and deadly tumor types

1. Estimated new cases and deaths from National Cancer Institute for 2020.
2. Estimated patients receiving chemotherapy from Kantar Health CancerMPact Patient Metrics, 2019 data based on IQVIA BrandImpact regimen shares and Kantar Health Treatment Architecture

2019 survey data for patients receiving chemo (rounded to nearest 5,000 patients).	22

Broad Portfolio of Impactful Studies Across Tumor Types

Cancer	Indication	Study	Phase 2	Pivotal	Approval
Type	Size
Lung	SCLC	NA			Under Priority Review with FDA
2L / 3L NSCLC	TBD	Starting 1H 2021
	(Post-checkpoint treatment)
Colorectal
1L CRC	~300			Ongoing
	1L TNBC1	~170		Starting 1H 2021
Breast	2L TNBC1	~80	Starting 1H 2021
(Post-checkpoint treatment)
	Neoadjuvant	Adaptive	Ongoing
Bladder	1L Bladder	TBD	Starting 1H 2021
(Checkpoint combination)

Two registrational studies will be ongoing by mid 2021 in addition to multiple Phase 2

studies to evaluate trilaciclib in several treatment settings / tumor types

1. 1L TNBC and 2L TNBC cohorts being conducted under one study protocol.

23

Ongoing First-Line CRC Pivotal Trial

FOLFOXIRI: most efficacious chemo regimen but highly myelosuppressive Ability to significantly expand FOLFOXIRI usage supported by market research

Treatment Phase

P R I M A R Y E N D P O I N T:

Randomization 1:1

						Myelopreservation
	14-day cycles			14-day cycles
	Induction Phase			Maintenance Phase
Day 1	Day 2	Day 14		Day 1	Day 2	SECONDARY ENDPOINTS:
	PFS/OS, PRO
Cycle X	Cycle X	Cycle X		Cycle X	Cycle X
Placebo +	Placebo			Placebo +	Placebo	TARGET ENROLLMENT:
FOLFOXIRI +	+ CI FU			bev + CI FU	+ CI FU
bevacizumab						~300 participants
Trilaciclib +	Trilaciclib			Trilaciclib	Trilaciclib	PATIENTS TREATED UNTIL
FOLFOXIRI +	+ CI FU			+ bev + CI FU	+ CI FU
bevacizumab						PROGRESSION
						MULTI-DAY CHEMO
	Maximum of 12 cycles			Until Progression	REGIMEN

Strong support from preclinical models for the benefits of trilaciclib

in combination with 5-FU-based chemo regimens

24

Metastatic TNBC is an Area of High Unmet Need

Breast Cancer Subtypes

	HER2 +
	TNBC
HR +	(15% - 20%)

• TNBC tumors categorized by lack of HR expression and HER2 gene amplification
• Tumors are aggressive and difficult to treat
• Targeted therapies only demonstrated benefit in subpopulations (e.g., PD-L1 agents, PARPs)
• Antibody Drug Conjugates (ADCs) demonstrated OS improvement in 3L to date, but have associated toxicity

Urgent need for new therapies that extend Overall Survival with decreased toxicity

25

Observed Robust OS Improvement in mTNBC Phase 2

Overall Survival in Intent-to-Treat Population1

			Treatment Group2	Median OS,	Hazard Ratio	P Value
Group 2 (trila + gem/carbo)	2			months	(95% CI)
	Group 1:	12.6	-	-
Group 3 (trila + gem/carbo)2		(gem/carbo)

	Group 2:	Not Reached	0.31	0.0016
	(gem/carbo + trilaciclib)	(0.15-0.63)
Group 1 (gem/carbo)2
Group 3:	17.8	0.40	0.0004
	(gem/carbo + trilaciclib)	(0.22-0.74)

Observed a robust statistically significant improvement in Overall Survival

for both trilaciclib schedules

1. O'Shaughnessy et al., 2020 San Antonio Breast Cancer Symposium (SABCS), Poster #PD1-06. Note: primary endpoints relating to reduction in severe neutropenia not achieved in this study.
2. Patients randomized to receive gem/carbo chemotherapy only (Group 1) or gem/carbo plus one of two dosing schedules of trilaciclib: trilaciclib administered on the day of chemotherapy (Group 2)

or trilaciclib administered the day prior to and the day of chemotherapy (Group 3).	26

OS Improvement Regardless of PD-L1 Status

Overall Survival for PD-L1 Positive Tumors1

		Median OS	Hazard Ratio
Treatment Group2	Patients	(95% CI),	P Value
(95% CI)
		Months
Group 1:	17	10.5	-	-
(gem/carbo)	(6.3 - 18.8)
Group 2 and 3:	32	32.7	0.34	0.004
(gem/carbo + trilaciclib)	(17.7 - NR)	(0.2 - 0.7)

Overall Survival for PD-L1 Negative Tumors1

		Median OS	Hazard Ratio
Treatment Group2	Patients	(95% CI),	P Value
(95% CI)
		Months
Group 1:	10	13.9	-	-
(gem/carbo)	(12.6 - NR)
Group 2 and 3:	26	17.8	0.48	0.093
(gem/carbo + trilaciclib)	(13.1 - NR)	(0.2 - 1.2)

Overall Survival improvement was observed regardless of tumor PD-L1 status

(greater effect in PD-L1 positive tumors)

1. O'Shaughnessy et al., 2020 San Antonio Breast Cancer Symposium (SABCS), Poster #PD1-06. Note: primary endpoints relating to reduction in severe neutropenia not achieved in this study.
2. Patients randomized to receive gem/carbo chemotherapy only (Group 1) or gem/carbo plus one of two dosing schedules of trilaciclib: trilaciclib administered on the day of chemotherapy (Group 2)

or trilaciclib administered the day prior to and the day of chemotherapy (Group 3).	27

Initiating TNBC Pivotal Trial (1L and 2L Cohorts) in 1H 2021

Strong evidence of efficacy across subsets and line of treatment in Phase 2 trial

Evaluating 1L checkpoint-naïve and 2L checkpoint-experienced patients

				P R I M A R Y E N D P O I N T:
Cohort 1:	1:1		GC on Days 1 and 8 every 21 days until	Overall survival
1L TNBC		SECONDARY ENDPOINTS:
Randomization		progression
(checkpoint naive)		PRO, myelopreservation
Cohort 2:			trilaciclib + GC on Days 1 and 8 every 21	measures, PFS/ORR
2L TNBC			TARGET ENROLLMENT:
		days until progression
(post-checkpoint)			~170 1L and ~80 2L
				participants

Pivotal study evaluating trilaciclib in mTNBC (PD-L1 positive and negative patients)

complements ongoing I-SPY 2 Phase 2 Neoadjuvant BC study

28

Initiating Two Additional Trilaciclib Phase 2 Trials in 1H 2021

1L Bladder Study (anti-PD-L1 combination)

Strong rationale for trilaciclib + chemo + I/O in 1L bladder cancer

• Known immunogenic tumor responsive to chemo + I/O
• Data suggests synergistic effect of trilaciclib + checkpoint1-3
• Similar chemo as TNBC study (gemcitabine/platinum)
• Benefits of treating patients until progression

Interim data expected in late 2022

• Primary aim to evaluate anti-tumor efficacy
• Randomized open-label study design

2L / 3L NSCLC Study (post-checkpoint)

Important area to demonstrate benefits of trilaciclib in post-checkpoint setting

• Known immunogenic tumor
• Trilaciclib mechanism is distinct from checkpoints
• High unmet need as treatment options limited in 2L / 3L
• Complementary commercial fit with SCLC indication

Interim data expected in early 2023

• Primary aim to evaluate anti-tumor efficacy
• Randomized double-blind study

Important future expansion areas for trilaciclib with data available in next 2 - 3 years

1. Lai et al., Journal for ImmunoTherapy of Cancer 2020; 8:e000847. doi:10.1136/jitc-2020-000847.
2. Deng et al., Cancer Discov. 2018;8(2):216- 33.

3. Daniel et al., 2019 European Society for Medical Oncology (ESMO), Abstract # 1742PD	29

2021 Key Objectives

1. Obtain U.S. approval for ES-SCLC and successfully launch trilaciclib in 1Q
2. Establish trilaciclib as Standard of Care for ES-SCLC patients in the U.S.
3. Maximize long-term value of trilaciclib by executing robust development plan
4. Evaluate partnership options for rintodestrant following combination data readout in 2Q
5. Continue managing investor capital efficiently

30

Rintodestrant Demonstrates a Favorable Oral SERD* Profile

Fulvestrant is currently only SERD available

• Proven approach but painful intramuscular injections limit use to 2L and preclude use in earlier lines of therapy
• An oral SERD has potential to move into earlier lines of ER- positive breast cancer therapy

Rintodestrant monotherapy Phase 1b findings to date:

• Favorable tolerability - AEs mostly Grade 1 or Grade 2
• Strong ER target engagement/occupancy with evidence of anti-tumor activity in heavily pre-treated patients

40-patient Phase 2 combination trial with CDK4/6 inhibitor palbociclib ongoing; data in 2Q21

Phase 2 combination data will be important to help secure partner to fund Phase 3 investment

* SERD = Selective Estrogen Receptor Degrader

Next steps will be evaluated following data readout expected in 2Q21

31

2021 Key Objectives

1. Obtain U.S. approval for ES-SCLC and successfully launch trilaciclib in 1Q
2. Establish trilaciclib as Standard of Care for ES-SCLC patients in the U.S.
3. Maximize long-term value of trilaciclib by executing robust development plan
4. Evaluate partnership options for rintodestrant following combination data readout in 2Q

32

Continue to Efficiently Manage Capital

• ~$207M cash at year-end 2020 provides runway into second half of 2022
• Efficiently executing plan with lean organization of ~125 FTEs
• • Utilizing capital efficient promotion arrangement with Boehringer Ingelheim for trilaciclib U.S. launch in SCLC
  • Expect to leverage co-development opportunities with partner Simcere for potential cost and timing efficiencies
• Access to debt facility up to $100M total ($20M drawn to date)
• Potential future milestones (up to $486M) and royalties from licensing agreements

Efficiently managing capital with a lean organization and benefiting from existing partnership arrangements

33

Maximizing Value of Trilaciclib

Key Study Objective:

Myelopreservation

Improved Survival (single agent)

Improved Survival (combinations)

		REGISTRATIONAL TRIALS
POTENTIAL			1L / 2L TNBC
		Data Readout:
U.S. APPROVAL		1L CRC
			2H 2023

	Data Readout:
ES-SCLC
1H 2023
Launch:
1Q 2021

			PHASE 2 STUDIES
						+ Milestones and
									Royalties
						Other Tumors
						TBD
					1L Bladder
					Cancer
			2L / 3L NSCLC		Data Readout:
				2H 2022
								Trilaciclib
	Neoadjuvant		Data Readout:
	Breast Cancer		1H 2023						Opportunity

Data Readout:

2H 2023

Expect ES-SCLC launch in 1Q 2021 and multiple data readouts

to drive expansion and long-term growth

34